Head and Neck
Clinical Trial A091101:
- Locally or regionally advance squamous cell carcinoma. Patients with Stage III hypopharynx or Stage IV a-b squamous cell carcinoma (other than oropharyngeal) or Stage IV a-b HPV negative oropharyngeal may be eligible. Participants will be treated with Taxotere/Cisplatin and ABT888 followed by Cisplatin and Radiation Therapy. Participants must have measurable disease and be able to swallow.
- Exclusions include, but are not limited to: Seizure disorders, impaired gastrointestinal function, HIV (currently on antiviral cocktail), chronic systemic steroid use and unstable angina, cardiac arrhythmia or infection.